152 related articles for article (PubMed ID: 38351809)
41. Monitoring minimal/measurable residual disease in B-cell acute lymphoblastic leukemia by flow cytometry during targeted therapy.
Liu Z; Li Y; Shi C
Int J Hematol; 2021 Mar; 113(3):337-343. PubMed ID: 33502735
[TBL] [Abstract][Full Text] [Related]
42. Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia.
Kruse A; Abdel-Azim N; Kim HN; Ruan Y; Phan V; Ogana H; Wang W; Lee R; Gang EJ; Khazal S; Kim YM
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32033444
[TBL] [Abstract][Full Text] [Related]
43. Immunophenotyping of Acute Lymphoblastic Leukemia.
DiGiuseppe JA; Cardinali JL
Methods Mol Biol; 2019; 2032():297-310. PubMed ID: 31522425
[TBL] [Abstract][Full Text] [Related]
44. A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups.
Scrideli CA; Assumpção JG; Ganazza MA; Araújo M; Toledo SR; Lee ML; Delbuono E; Petrilli AS; Queiróz RP; Biondi A; Viana MB; Yunes JA; Brandalise SR; Tone LG
Haematologica; 2009 Jun; 94(6):781-9. PubMed ID: 19483156
[TBL] [Abstract][Full Text] [Related]
45. Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children's oncology group.
Borowitz MJ; Pullen DJ; Winick N; Martin PL; Bowman WP; Camitta B
Cytometry B Clin Cytom; 2005 Nov; 68(1):18-24. PubMed ID: 16184615
[TBL] [Abstract][Full Text] [Related]
46. Association of Minimal Residual Disease by a Single-Tube 8-Color Flow Cytometric Analysis With Clinical Outcome in Adult B-Cell Acute Lymphoblastic Leukemia: A Real-World Study Based on 486 Patients.
Liao H; Jiang N; Yang Y; Zhang X; Chen J; Lai H; Zheng Q
Arch Pathol Lab Med; 2023 Oct; 147(10):1186-1195. PubMed ID: 36508349
[TBL] [Abstract][Full Text] [Related]
47. Minimal residual disease monitoring cannot fully replace bone marrow morphology in assessing disease status in pediatric acute lymphoblastic leukemia.
Rathe M; Preiss B; Marquart HV; Schmiegelow K; Wehner PS
APMIS; 2020 May; 128(5):414-419. PubMed ID: 32108963
[TBL] [Abstract][Full Text] [Related]
48. Participation in the College of American Pathologists Laboratory Accreditation Program Decreases Variability in B-Lymphoblastic Leukemia and Plasma Cell Myeloma Flow Cytometric Minimal Residual Disease Testing: A Follow-up Survey.
Hupp MM; Bashleben C; Cardinali JL; Dorfman DM; Karlon W; Keeney M; Leith C; Long T; Murphy CE; Pillai V; Rosado FN; Seegmiller AC; Linden MA
Arch Pathol Lab Med; 2021 Mar; 145(3):336-342. PubMed ID: 32886757
[TBL] [Abstract][Full Text] [Related]
49. Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL.
Lúcio P; Parreira A; van den Beemd MW; van Lochem EG; van Wering ER; Baars E; Porwit-MacDonald A; Bjorklund E; Gaipa G; Biondi A; Orfao A; Janossy G; van Dongen JJ; San Miguel JF
Leukemia; 1999 Mar; 13(3):419-27. PubMed ID: 10086733
[TBL] [Abstract][Full Text] [Related]
50. Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: potential usefulness in minimal residual disease detection.
DiGiuseppe JA; Fuller SG; Borowitz MJ
Cytometry B Clin Cytom; 2009 Mar; 76(2):150-5. PubMed ID: 18831072
[TBL] [Abstract][Full Text] [Related]
51. Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value.
Vidriales MB; Pérez JJ; López-Berges MC; Gutiérrez N; Ciudad J; Lucio P; Vazquez L; García-Sanz R; del Cañizo MC; Fernández-Calvo J; Ramos F; Rodríguez MJ; Calmuntia MJ; Porwith A; Orfao A; San-Miguel JF
Blood; 2003 Jun; 101(12):4695-700. PubMed ID: 12586618
[TBL] [Abstract][Full Text] [Related]
52. Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting.
Irving J; Jesson J; Virgo P; Case M; Minto L; Eyre L; Noel N; Johansson U; Macey M; Knotts L; Helliwell M; Davies P; Whitby L; Barnett D; Hancock J; Goulden N; Lawson S; ;
Haematologica; 2009 Jun; 94(6):870-4. PubMed ID: 19377076
[TBL] [Abstract][Full Text] [Related]
53. Immunological detection of minimal residual disease in acute lymphoblastic leukemia.
Dworzak MN
Onkologie; 2001 Oct; 24(5):442-8. PubMed ID: 11694770
[TBL] [Abstract][Full Text] [Related]
54. Utilizing the prognostic impact of minimal residual disease in treatment decisions for pediatric acute lymphoblastic leukemia.
Ceppi F; Rizzati F; Colombini A; Conter V; Cazzaniga G
Expert Rev Hematol; 2021 Sep; 14(9):795-807. PubMed ID: 34374613
[TBL] [Abstract][Full Text] [Related]
55. Detection of minimal residual disease in acute leukemia.
van der Velden VH; Boeckx N; van Wering ER; van Dongen JJ
J Biol Regul Homeost Agents; 2004; 18(2):146-54. PubMed ID: 15471219
[TBL] [Abstract][Full Text] [Related]
56. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study.
Holowiecki J; Krawczyk-Kulis M; Giebel S; Jagoda K; Stella-Holowiecka B; Piatkowska-Jakubas B; Paluszewska M; Seferynska I; Lewandowski K; Kielbinski M; Czyz A; Balana-Nowak A; Król M; Skotnicki AB; Jedrzejczak WW; Warzocha K; Lange A; Hellmann A
Br J Haematol; 2008 Jun; 142(2):227-37. PubMed ID: 18492099
[TBL] [Abstract][Full Text] [Related]
57. Standardizing minimal residual disease by flow cytometry for precursor B lineage acute lymphoblastic leukemia in a developing country.
Patkar N; Alex AA; B B; Ahmed R; Abraham A; George B; Vishwabandya A; Srivastava A; Mathews V
Cytometry B Clin Cytom; 2012 Jul; 82(4):252-8. PubMed ID: 22467604
[TBL] [Abstract][Full Text] [Related]
58. Measurable residual disease study through three different methods can anticipate relapse and guide early interventions in childhood acute lymphoblastic leukemia.
Ramos Elbal E; Fuster JL; Campillo JA; Galera AM; Cortés MB; Llinares ME; Jiménez I; Plaza M; Martínez Banaclocha H; Galián JA; Blanquer Blanquer M; Martínez Sánchez MV; Muro M; Minguela A
Clin Transl Oncol; 2024 Jan; 26(1):278-287. PubMed ID: 37368200
[TBL] [Abstract][Full Text] [Related]
59. Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia.
Denys B; van der Sluijs-Gelling AJ; Homburg C; van der Schoot CE; de Haas V; Philippé J; Pieters R; van Dongen JJ; van der Velden VH
Leukemia; 2013 Mar; 27(3):635-41. PubMed ID: 22945774
[TBL] [Abstract][Full Text] [Related]
60. Flow-cytometric detection of minimal residual disease in adult acute lymphoblastic leukemia.
Krampera M; Perbellini O; Maggioni A; Scognamiglio F; Todeschini G; Pizzolo G
Haematologica; 2001 Mar; 86(3):322-3. PubMed ID: 11255283
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
